Editorial: A Contemporary Update of Sinusitis: Pathogenesis,Diagnosis & Treatment,Management of Complications and Research Techniques

Mechanisms and Modifiers of Disease

Reviews of endotype-specific inflammation clarify how Type 2 and non-Type 2 pathways manifest clinically and discuss therapy selection. ¹ Complementing these immunologic perspectives, environmental and inhalational exposures—including tobacco smoke, occupational irritants, ambient air pollution, particulate matter, and wildfire smoke—are synthesized with population-level and mechanistic data, underscoring how the external environment shapes sinonasal disease burden and outcomes. ² At the tissue level, original research demonstrates how myofibroblast activity (α-SMA) in nasal polyps correlates with clinical severity and imaging findings. ³ Respiratory epithelial adenomatoid hamartoma (REAH) is contextualized within chronic sinonasal inflammation, illustrating patterning across comorbid CRSwNP, perennial allergy, and AERD. ⁴

Diagnosis, Endotyping, and Emerging Tools

Olfactory assessment represents established clinical practice: psychophysical tests such as UPSIT, BSIT, and Sniffin’ Sticks are validated, widely used instruments, and a comparative review provides pragmatic, cost-sensitive recommendations for diagnosing and monitoring olfactory dysfunction that frequently accompanies CRS—a domain that has gained renewed clinical attention since the COVID-19 pandemic. ⁵ These tools can and should be incorporated into the routine diagnosis and evaluation of patients presenting with olfactory complaints.

Current endotyping of CRS relies on clinical observation for nasal polyps; however, as biologic treatments become more common, better endotyping methods will be required to select patients for specific therapies. Cytokine sampling methods, currently used in research studies—including nasal lavage, epithelial lining fluid, swabs/sponge, suction, and biopsy are reviewed with practical guidance on matching these strategies to analytic goals to help investigators select the most appropriate approach. ⁶ Similarly, sinonasal microbiome analysis remains investigational. Conventional sequencing approaches have historically lacked species-level resolution, limiting the ability to distinguish pathogenic from commensal bacteria. Long-read 16S rRNA sequencing represents an emerging advance that offers greater taxonomic precision and may reveal dysbiosis signatures to better inform future treatment strategies, though its routine clinical application is still being defined. ⁷

Medical Therapy, Biologics, and Peri-Operative Care

Therapeutics have evolved. A comprehensive review distills biologic options for CRSwNP—dupilumab, omalizumab, mepolizumab—and emerging biologics, with clear attention to indications, mechanisms, side-effects, dosing, cost, and real-world use. ⁸ The biologic landscape continues to expand beyond these established agents; emerging therapies targeting upstream and IL-5–related pathways—including TSLP inhibition with tezepelumab and longer-acting biologics will continue to strengthen our armamentarium for patients with refractory type 2 airway inflammation. Recognizing CRSwNP within the broader “united airway” paradigm, where upper and lower airway disease share common inflammatory mechanisms, will be increasingly important as these agents move through clinical development and into practice, typically initially being approved for asthma before approval for CRS.

For patients undergoing surgery a review of post sinus surgery care translates the evidence into practical algorithms: multimodal analgesia prioritizing acetaminophen and NSAIDs, routine high-volume saline irrigation, judicious topical steroids, selective antibiotics, and context-dependent use of packing/stents/spacers and debridement. ⁹ Together, these papers emphasize that medical therapy and surgery are complementary, not competing, elements of comprehensive care.

Surgical Innovation and Translational Modeling

Beyond clinical technique, this issue features computational fluid dynamics (CFD) modeling that quantifies how ESS changes airflow, pressure, heat transfer, and nasal spray deposition. The work demonstrates practical insights (e.g., spray angle effects, bilateral asymmetry) that may inform device selection, patient coaching, and future trial designs aimed at improving targeted drug delivery in the post-operative nose. ¹⁰ These translational methods help bridge the gap between anatomy, physics, and pharmacology—moving us closer to individualized, anatomy-aware care.

Complex Phenotypes: AFRS and AERD

Allergic fungal rhinosinusitis (AFRS) and aspirin-exacerbated respiratory disease (AERD) represent severe, distinct CRS phenotypes requiring nuanced management. Updated reviews detail AFRS epidemiology—including links to social determinants of health—diagnostic limitations of Bent and Kuhn criteria, and evolving therapeutic strategies incorporating ESS, topical steroids, antifungals, and biologics. ¹¹ Original outcomes data for AERD demonstrate that structured care pathways combining ESS and aspirin desensitization yield faster symptom improvement, reduced inhaled medication burden, and lower revision surgery rates. ¹² These findings underscore the importance of phenotype-specific strategies integrated into multidisciplinary care.

Complications: Recognition, Intervention, and Collaboration

While many cases of sinusitis resolve uneventfully, complications remain clinically consequential. Reviews in this issue outline orbital and intracranial complications—their risk factors, imaging strategies, and management principles—calling for early recognition and coordinated ENT, ophthalmology, and neurosurgery care pathways to minimize morbidity. ¹³ A dedicated pediatric narrative review clarifies Chandler staging, surgical indications (e.g., abscess size/location, vision findings), and antibiotic strategies, offering practical guidance for high-risk, time-sensitive scenarios. ¹⁴